https://www.selleckchem.com/pr....oducts/sodium-hydrox
67 versus 1.23 per patient and 0.59 versus 0.25 per cycle. Likewise, febrile neutropenia happened 106 versus 21 cases, 2.52 versus 0.52 per patient and 0.41 versus 0.11 per cycle. EVS is higher in group B 33% versus 79% (2-year), and 24% versus 69% (5-year). Current therapeutic protocols have shown higher EFS due to better safety profile, with less haematological, neurological and haemorrhagic toxicity, as well as lower rates of infectious complications. Current therapeutic protocols have shown higher EFS due to better safety p
Like
Comment
Share
